Quatrx Pharmaceuticals Presents Results From Ophena™ (Ospemifene Tablets) Phase 3 Study Related To Treatment Of Symptoms Of Vulvovaginal Atrophy
Released June 16, 2008

QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena™ (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
Released May 21, 2008

Phase 1 Studies Show Promise of QuatRx’s Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
Released January 29, 2008

QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
Released January 4, 2008

QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena™ (Ospemifene) to Treat Postmenopausal Vaginal Syndrome
Released January 3, 2008

QuatRx Completes Patient Enrollment In Phase 3 Study Of Ophena™ In Women With Postmenopausal Vaginal Syndrome
Released August 22, 2007

QuatRx Pharmaceuticals Company Closes $44 Million Series E Private Equity Financing
Released May 22, 2007

CollaGenex Pharmaceuticals and QuatRx Pharmaceuticals Announce Agreement for the Development and Commercialization of Becocalcidiol
Released May 16, 2007

Quatrx Pharmaceuticals Reports Positive Results From A Phase 2 Trial Of Fispemifene
Released January 8, 2007

Quatrx Pharmaceuticals Initiates Phase I Trial for Treatment to Reduce Both LDL Cholesterol and Lipoprotein (a)
Released September 28, 2006

Quatrx Pharmaceuticals Announces New Management Appointments
Released September 19, 2006

Quatrx Pharmaceuticals Withdraws Registration Statement For Initial Public Offering
Released July 10, 2006

QuatRx Pharmaceuticals to Expand Portfolio of Products in Women's Health Through Development Program for HSD Inhibitors
Released June 22, 2006

Quatrx Pharmaceuticals Advances U.S. Clinical Trials For Fispemifene And Ospemifene; Richard Fox Joins Board Of Directors
Released February 17, 2006

Quatrx Pharmaceuticals Files Registration Statement For Initial Public Offering
Released February 06, 2006

Anders P. Wiklund Joins QuatRx Board Of Directors
Released October 24, 2005

QuatRx Announces The Appointment Of Jeffery Brinza As General Counsel
Released July 18, 2005

QuatRx Pharmaceuticals announces results from Phase 2b clinical study Of Becocalcidiol in Psoriasis
Released June 14, 2005

QuatRx Pharmaceuticals announces merger with Hormos Medical
Released May 16, 2005

Hormos licenses HMRlignan™ to Linnea
Released April 18, 2005

QuatRx Pharmaceuticals licenses novel Lipid-Lowering Drug
Released March 15, 2005

QuatRx Pharmaceuticals raises $31 million in third private equity financing
Released December 13, 2004

August Watanabe, M.D., Elected To Board Of Directors of QuatRx Pharmaceuticals company
Released September 22, 2003

QuatRx Pharmaceuticals Completes Private Equity Financing
Released June 10, 2003

QuatRx Pharmaceuticals Licenses Portfolio of Novel Cholesterol Drugs
Released May 21, 2003

Hormos Medical and Solvay Pharmaceuticals Sign a Research and License Agreement
Released February 20, 2003

QuatRx Pharmaceuticals Initiates Phase II Study Of Lead Compound In Patients With Psoriasis
Released January 22, 2003

QuatRx raises $10 M in venture capital funding. Acquires rights to novel vitamin-D analogues and protein delivery technology
Released January 23, 2002